Macro: Sandcastle economics
Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.
Technical Analyst, Saxo Bank Group
Eli Lilly LLY (Weight loss and Diabetes drug competitor to Novo Nordisk) formed yesterday a Bearish Engulfing top and reversal pattern on the daily chart
The RSI indicator has been in overbought territory at at extreme level at 90. However, there is no divergence indicating higher levels could be seen but the Bearish Engulfing pattern is a fairly strong top and reversal indicator.
If LLY is closing below 725 it could be hit with a larger corrective sell-off down to the gap area at 691.
Bears will then try to closing the gap i.e., trying to push LLY down to 667.65.
On the weekly chart LLY could also here be in the process of forming a Bearish Engulfing top and reversal pattern
RSI divergence has been indicating uptrend exhaustion for a few weeks by now.
The bearish/corrective scenario is quite likely to unfold if LLY is closing the week below 740.80 (horizontal dashed blue line)
If that scenario plays out a larger sell-off could hit the share price and the Consolidation area between 612 and 560 could come in to play. However, the gap are is a quite strong support area
To demolish the top and reversal pattern a close above the peak at 793.38 is needed.
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)